Atripla (Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate) for HIV

Overview
Atripla is a prescription drug approved by the Food and Drug Administration (FDA) to treat HIV-1 infection either alone or in combination with other antiretroviral medications. Atripla is approved for use in people 12 years and older. Atripla is a combination drug composed of Efavirenz, Emtricitabine, and Tenofovir disoproxil fumarate, which are also known respectively by the abbreviations EFV, FTC, and TDF. Efavirenz is an antiretroviral drug of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. Emtricitabine and Tenofovir disoproxil fumarate are both antiretroviral medications of the nucleoside reverse transcriptase inhibitor (NRTI) class. All three drugs are believed to work by preventing HIV from replicating in cells.

How do I take it?
Prescribing information states that Atripla is taken once daily. Atripla comes in tablet form.

Side effects
The FDA-approved label for Atripla lists common side effects including headache, dizziness, depression, insomnia, strange dreams, fatigue, rash, nausea, and diarrhea. Rare but serious side effects listed for Atripla include lactic acidosis (a metabolic disorder), hepatomegaly (enlarged liver) with steatosis (fatty degeneration), and severe exacerbation of Hepatitis B.

For more details about this treatment, visit:

Atripla highlights of prescribing information – Bristol-Myers Squibb

Overview of HIV Treatments – AIDS.gov